Cryoport Intrinsic Value Calculation – AXA S.A. Boosts Investment in Cryoport, with Increased Holdings

☀️Trending News

AXA S.A., a multinational insurance and investment firm, has recently announced an increase in its investment in Cryoport ($NASDAQ:CYRX), Inc. This comes as a significant move for both companies, as AXA S.A. has recognized the potential for growth and success in Cryoport’s business. For those unfamiliar with Cryoport, it is a leading global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in the transportation of critical products, such as cell and gene therapies, vaccines, and other biologic materials, that require strict temperature control to maintain their efficacy. With the rapid advancements in the biotech and pharmaceutical industries, the demand for Cryoport’s services has been steadily increasing. This recent increase in investment further solidifies AXA’s confidence in the company’s business model and future prospects. This move also highlights AXA’s commitment to investing in innovative and emerging companies that have the potential to disrupt and transform industries. Cryoport has been making significant strides in expanding its global reach and strengthening its market position.

Additionally, Cryoport has been actively expanding its international presence by establishing operations and partnerships in key regions such as Europe, Asia, and Latin America. The increased investment from AXA S.A. will provide Cryoport with additional resources to continue its growth trajectory and capitalize on emerging opportunities in the life sciences industry. It will also help the company to further develop its advanced technology and infrastructure, ensuring the safe and efficient transport of critical biological materials. With AXA’s support, Cryoport is well-positioned to continue its expansion and solidify its position as a leader in the industry. Overall, this increased investment is a positive development for both companies and showcases the potential for collaboration between the insurance and life sciences sectors.

Market Price

On Friday, AXA S.A., a leading global insurance and investment management company, announced that it had increased its investment in Cryoport, Inc. This move further solidifies AXA’s confidence in the biopharmaceutical logistics company, which specializes in providing solutions for the handling and transport of temperature-sensitive materials. The day’s trading saw Cryoport’s stock open at $8.11 and close at $8.0, representing a 0.38% increase from the previous day’s closing price of $7.97. This boost in stock price can be attributed to AXA’s increased stake in the company, as well as their continued support and belief in Cryoport’s potential for growth and success. This increased investment from AXA comes at a time when Cryoport is experiencing significant growth and expansion in the biopharmaceutical market. With the rise in demand for temperature-sensitive materials, particularly in the development and transportation of cell and gene therapies, Cryoport has positioned itself as a key player in the industry.

AXA’s increased holdings in Cryoport also reflect their confidence in the company’s recent performance and future outlook. Overall, AXA’s increased investment in Cryoport is a clear indication of their belief in the company’s potential for growth and success in the rapidly expanding biopharmaceutical logistics market. As Cryoport continues to innovate and expand its services, it is likely that we will see further support from investors like AXA, driving the company towards even greater achievements. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Cryoport. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Cryoport. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Cryoport. More…

Key Ratios Snapshot

Some of the financial key ratios for Cryoport are shown below. More…

Analysis – Cryoport Intrinsic Value Calculation

As an independent research firm, GoodWhale has thoroughly examined CRYOPORT‘s core principles and business strategies. We have found that the company places a strong emphasis on innovation, quality, and customer satisfaction. CRYOPORT’s pioneering technology in temperature-controlled logistics has helped it establish a dominant position in the biopharmaceutical industry. In addition to its impressive core principles, CRYOPORT’s financial performance has also caught our attention at GoodWhale. Our comprehensive evaluation of the company’s financials has led us to determine a fair value of $35.1 for CRYOPORT’s share price, based on our proprietary Valuation Line. This valuation takes into account various factors such as revenue growth, profitability, and industry trends. However, despite CRYOPORT’s strong fundamentals and promising future prospects, we have observed that its current stock price is significantly undervalued. At a trading price of $8.0, CRYOPORT’s stock is undervalued by 77.2% according to our calculations. This presents a clear opportunity for investors to acquire shares at a discount and potentially reap significant returns in the future. At GoodWhale, we believe that CRYOPORT’s cutting-edge technology and commitment to excellence make it a highly attractive investment opportunity. We are confident that the company will continue to thrive and deliver value to its stakeholders, making it a solid choice for long-term investors. More…

Peers

In the logistics and transportation industry, there is intense competition among companies to provide the most efficient and cost-effective services. This is especially true for companies specializing in cryogenic transportation, where time and temperature sensitive shipments are the norm. In this arena, CryoPort Inc. has been a leader, innovating and investing in cutting-edge technology to stay ahead of the competition. Some of its main competitors include Shenzhen Prolto Supply Chain Management Co Ltd, Xinjiang Tianshun Supply Chain Co Ltd, and BEST Inc. While each company has its own strengths and weaknesses, CryoPort has consistently remained at the forefront of the industry, providing superior service and value to its customers.

– Shenzhen Prolto Supply Chain Management Co Ltd ($SZSE:002769)

Shenzhen Prolto Supply Chain Management Co Ltd has a market cap of 3.23B as of 2022, and a Return on Equity of 2.47%. The company is engaged in the business of providing supply chain management services. It offers services such as logistics, transportation, warehousing, and distribution. The company has a network of over 1,000 warehouses in China.

– Xinjiang Tianshun Supply Chain Co Ltd ($SZSE:002800)

Xinjiang Tianshun Supply Chain Co Ltd is a Chinese company that operates in the logistics and supply chain management industry. The company has a market capitalization of 2.2 billion US dollars as of 2022 and a return on equity of 6.85 percent. Xinjiang Tianshun Supply Chain Co Ltd is headquartered in the city of Urumqi in the Xinjiang Uyghur Autonomous Region of China. The company was founded in the year 2006.

– BEST Inc ($NYSE:BEST)

BEST Inc. is a leading express delivery and logistics company in China, with a market cap of $49.1 million as of 2022. The company has a return on equity of -60.92%. BEST Inc. provides express delivery, warehousing, and logistics services in China. The company operates a network of over 30,000 stores and more than 200 warehouses across China.

Summary

Axa S.A., a leading global financial services company, has increased its investments in Cryoport, Inc. This indicates a positive outlook on the company’s future prospects and potential for growth. Cryoport, Inc. is a small-cap company that offers advanced cold chain logistics solutions for the life sciences industry. The increasing investments from Axa S.A. suggest that the company’s financial performance and market position are attracting the attention of institutional investors. This may be a reassuring sign for potential investors looking to invest in Cryoport, Inc., as it indicates a level of confidence in the company’s ability to deliver strong returns in the long term.